RedHill Biopharma Announces Q3/22 Results and Operational Hi

Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt obligations, to facilitate growth Q3/22 Net revenues of $17.6...

Related Keywords

United States , New York , Israel , State Of New York , American , Dror Ben Asher , Redhill Biopharma , Adi Frish , Kukbo Co , Redhill Biopharma Inc , University Of Tennessee , International Journal Of Nephrology , Redhill Biopharma Ltd , Nasdaq , Company Annual Report On Form , Trademark Office , Development Expenses , Company Expanded Access Program , Centers For Disease , Zinsight Technology , European Commission , Supreme Court , Exchange Commission , Business Development , Animal Rule , Priority Review Voucher , Chief Executive Officer , Review Voucher , Administrative Expenses , Cash Used , Operating Activities , Financing Activities , Commercial Division , Subscription Agreement , Exclusive License Agreement , Preferred Status , Medicare Part , Disease Control , Obesity Week , World Gastro , Priority Review , United States Patent , International Journal , Renovascular Disease , Drug Design , Nontuberculous Mycobacteria , Orphan Drug Designation , Hill Biopharma , Private Securities Litigation Reform Act , Expanded Access Program , Annual Report , Markets Insight ,